This is a repository copy of *Compact, Polyvalent Mannose Quantum Dots as Sensitive, Ratiometric FRET Probes for Multivalent Protein-Ligand Interactions*.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/98102/

Version: Accepted Version

Compact, Polyvalent Mannose-Quantum Dots as Sensitive, Ratiometric FRET Probes for Multivalent Protein-Ligand Interactions**

Yuan Guo,* Chadamas Sakonsinsiri, Inga Nehlmeier, Martin A. Fascione, Haiyan Zhang, Weili Wang, Stefan Pöhlmann, W. Bruce Turnbull, and Dejian Zhou*

Abstract: A highly-efficient cap-exchange approach for preparing compact, dense polyvalent mannose-capped quantum dots (QDs) has been developed. The resulting QDs have been successfully used to probe multivalent interactions of HIV/Ebola receptors DC-SIGN and DC-SIGNR (collectively termed as DC-SIGN/R) via a sensitive, ratiometric Förster resonance energy transfer (FRET) assay. The QD probes specifically bind DC-SIGN, but not its closely related receptor DC-SIGNR, which is further confirmed by its specific blocking of DC-SIGN engagement with the Ebola virus glycoprotein. Tuning the QD surface mannose valency reveals that DC-SIGN binds more efficiently to densely packed mannosides. A FRET-based thermodynamic study reveals the binding is enthalpy driven. This work establishes QD-FRET as a rapid, sensitive technique for probing structure and thermodynamics of multivalent protein-ligand interactions.

Over the past 15 years, quantum dot (QD)-Förster resonance energy transfer (FRET) technology has emerged as a powerful tool to address a broad range of biomedical questions because it combines the spectroscopic ruling ability of FRET and the stable, bright fluorescence of QD.[1] It has been widely used for bio-/enzymatic /environmental/intracellular sensing, bio-diagnostics, cell monitoring and tracking.[1, 2] Despite great progress, QD-FRET has not been applied to probe multivalent protein-ligand interactions which are widespread and crucial for many important biological events such as viral infection, immune response, cell signalling and its regulation.[3] This limitation is primarily due to a lack of an effective approach to prepare compact (hydrodynamic diameter, D_h < ca. 10 nm), biocompatible and dense polyvalent QDs which are essential for multivalent binding and sensitive FRET readout.[1b] Compact, biocompatible QDs have been prepared by cap-exchange using dihydrolipoic acid (DHLA) based ligands for sensing and imaging applications.[4] The requirement of using a large excess of ligand (e.g. ligand:QD molar ratio of 10^4-10^5:1) of current protocols,[4] however, makes it impractical to initiate direct QD cap-exchange using expensive custom ligands. Thus functional groups are mostly conjugated to cap-exchanged QDs using various coupling and bioconjugation approaches. It has been difficult to achieve high polyvalency (ca. >150) on compact, sub-10 nm QDs. Herein we have solved this problem by performing cap-exchange in a homogeneous solution using functional ligands appending a deprotonated DHLA moiety. Our approach greatly improved the cap-exchange efficiency, allowing for production of compact, dense polyvalent mannose-capped QDs using 20-200 fold less ligand than literature protocols. We demonstrate that such compact, polyvalent mannosyl-QDs can provide quantitative binding affinity and thermodynamic parameters for multivalent protein-glycan interactions underpinning HIV/Ebola viral infections via a sensitive, ratiometric FRET readout strategy.

Figure 1. (**A**) Chemical structure of the dihydrolipoic acid-poly (ethylene glycol)-mannose (DHLA-PEG$_n$-Man) ligands and the schematic of our QD cap-exchange procedure. (**B, C, D**) Tuning inter-glycan spacing via PEG linker length of DHLA-PEG$_n$-Man (n = ~13 (**B**) or 3 (**C**)) and diluting with a DHLA-zwitterion spacer ligand (**D**). (**E**) Cartoon of probing multivalent interactions between extracellular segment of DC-SIGN/R and QD-PEG$_n$-Man by FRET.

Here the dendritic cell receptor, DC-SIGN (one of the most important cell pathogen receptors)[5] and an endothelial cell receptor, DC-SIGNR, are employed as model multimeric proteins. These proteins recognize multiple mannose-containing glycans on the human immunodeficiency virus (HIV) and Ebola virus (EBOV) surface glycoproteins via their clustered carbohydrate-recognition-

[*] Dr. Y. Guo, C. Sakonsinsiri, Dr. H. Zhang, W. Wang, Dr. W. B. Turnbull, Dr. D. Zhou
School of Chemistry and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds LS2 9JT, UK
E-mail: y.guo@leeds.ac.uk (Y.G) and d.zhou@leeds.ac.uk (D.Z.)
Dr. M. A. Fascione
Department of Chemistry, University of York, Heslington, York YO10 5DD, UK
Dr. I. Nehlmeier, Prof. Dr. S. Pöhlmann
Infection Biology Unit, German Primate Center, Kellnerweg 4, 37077 Gottingen, Germany

domains (CRDs, **Fig. 1E**).[5] The resulting high affinity, multivalent binding can enhance viral infectivity. It is known that synthetic multivalent glycoconjugates can inhibit such interactions.[6] Despite sharing 77% amino acid identity and an overall tetrameric structure, DC-SIGN/R have shown to process notable differences in glycan binding affinity, specificity and viral transmission efficiency. For example, DC-SIGN recognizes and transmits some HIV strains more effectively than DC-SIGNR,[7] whereas only DC-SIGNR promotes West Nile Virus (WNV) infection with high efficiency.[8] Given individual CRD-mannose binding motifs are identical in DC-SIGN/R[5b] and the binding affinities are very weak (K_D ~mM),[9] such differences must stem from their different multivalent binding properties which are still poorly understood. We reasoned that a polyvalent mannose-QD conjugate would be useful for probing the CRD arrangements here because it combines features of weak individual CRD-mannose binding affinity and nanoscale spherical geometry. As a result, only the protein with CRDs facing the same direction can bind to the QD multivalently, leading to high affinity.

First, two multifunctional mannose-containing ligands were designed and synthesized (see SI for details). Each ligand comprises a DHLA moiety for strong chelative binding to QD surface Zn^{2+} ions; a poly (ethylene glycol, PEG) linker for resisting non-specific adsorption and imposing high stability and biocompatibility;[4] and a mannose residue for specific protein binding (abbreviated as DHLA-PEG_n-Man hereafter, where n = 3 or ~13 stands for uniform or mixed length linker containing 3 or an average of 13 PEG units, respectively, **Fig. 1A**).

The DHLA-PEG_n-Man ligands were subsequently employed to perform cap-exchange with hydrophobic CdSe/ZnS QDs (~4.2 nm diameter, λ_{EM} ~560 nm, SI, Fig. S1A) to make QD-PEG_n-Man probes. Cap-exchange was performed in homogenous solution (e.g. 1:1 v/v $CHCl_3$/MeOH) using deprotonated DHLA to facilitate the ligand exchange process and enhance their QD binding affinity because thiolates bind much more strongly to Zn^{2+} ions than thiols (SI, Section A4).[4a] Under such conditions, stable, biocompatible QD-PEG_n-Mans were readily prepared at a ligand:QD molar ratio of 500:1, a substantial 20-200 fold lower than literature protocols. Importantly, this improvement made it practical to directly initiate cap-exchange with hydrophobic QDs using precious functional mannose ligands. It also enabled us to achieve unprecedented levels of high glycan polyvalency (ca. 330±70 and 170±30 for QD-EG_3-Man and QD-PEG_{13}-Man) on compact sub-10 nm QDs (Fig. S1). This would be very difficult for other current literature methods. Furthermore, this method also facilitated tuning the density and spacing of glycans at the QD surface via dilution with a DHLA-zwitterion ligand (**Fig. 1D**). These advantageous properties made the QDs powerful FRET probes for investigating multivalent protein-glycan interactions for the 1st time. Interestingly, the average inter-Man distance in the QD-EG_3-Man was estimated as ~0.98 nm (see SI, Section A43), matching well to the inter-glycosylation spacing of ~1 nm found on the HIV surface glycoprotein, gp120.[10]

To probe the multivalent binding by FRET, DC-SIGN was labeled with Atto-594 dye (SI, Section A51/52) on a site-specifically introduced cysteine residue. The dye labeling did not affect its specific binding to a Sepharose-mannose column. The Atto-594-QD FRET pair had respectable Förster radius (R_0 = 4.7/5.0 nm for QD-EG_3-Man/QD-PEG_{13}-Man respectively, SI, Fig. S2). Binding of the labeled DC-SIGN to the QDs yielded significantly reduced QD fluorescence at 554 nm together with concurrently enhanced Atto-594 FRET signal at 626 nm (**Fig. 2A, B**), which was fully consistent with a QD-sensitized Atto-594 FRET mechanism. Stronger FRET signals and more severely quenched QD fluorescence were observed

for DC-SIGN binding to QD-EG_3-Man over QD-PEG_{13}-Man, indicating more efficient FRET in the former pair. Both bindings displayed excellent fits (R^2 > 0.99) by the single QD donor FRET with N identical acceptors model,[2] yielding QD-dye distances (r) of ~6.8/9.8 nm for QD-EG_3-Man/QD-PEG_{13}-Man, respectively (SI, Fig. S3). These r values roughly matched the sum of QD core radius plus respective fully extended ligand length (ca. 6.5 and 10.0 nm, SI, Fig. S1).


Figure 2. (A-E) Acceptor direct excitation background corrected fluorescence spectra of QD-PEG_n-Man (λ_{EM} = 554 nm, final C_{QD} = 40 nM) after binding to Atto-594 labeled proteins: (A): DC-SIGN + QD-PEG_{13}-Man; (B): DC-SIGN + QD-EG_3-Man; (C): DC-SIGNR + QD-PEG_{13}-Man; (D): DC-SIGNR + QD-EG_3-Man; (E): DC-SIGN CRD monomer + QD-EG_3-Man. **(F)** Relationship between the apparent FRET ratio (I_{626}/I_{554}) and protein concentration fitted to the Hill equation. **(G, H)** Luciferase activities of cell lysates of DC-SIGN/R expressing 293T cells after exposure to an Ebola virus glycoprotein-bearing, luciferase-encoding murine leukemia virus (MLV-EBOV-GP) vector in the presence of indicated amounts of QD-EG_3-Man in Dulbecco's modified eagle medium supplemented with 10% fetal bovine serum. A MLV vector bearing the vesicular stomatitis virus glycoprotein (MLV-VSV-G) was used as negative control. Cells transfected with empty plasmid (pcDNA) were used as additional negative controls. In panel (G), the reduction of EBOV-GP-dependent transduction by 250 nM QD-EG_3-Man was statistically significant from the 0 nM QD control (p = 0.024).

The observed FRET signal was completely diminished in the absence of Ca^{2+} (SI, Fig. S4), suggesting the signal was indeed the result of Ca^{2+}-dependent DC-SIGN-mannose binding.[11] Moreover, the FRET signal was effectively inhibited by free mannose in a dose-dependent manner, while galactose was much less effective at inhibiting this binding (SI, Fig. S5). This result agrees well with DC-SIGN's binding specificity for mannose over galactose.[11a] A higher mannose concentration (K_I) was required to inhibit DC-SIGN binding to QD-EG_3-Man than to QD-PEG_{13}-Man (1.4 v.s. 0.80 mM,

see **Table 1**), which was consistent with the former binding being tighter (apparent K_D 0.32 v.s. 0.6 μM).

Surprisingly, binding of DC-SIGNR (also labeled with Atto-594, SI, Section A51) to the QDs yielded only very weak FRET signals (**Fig. 2C & D**) which were barely stronger than that of the mono-meric CRD (**Fig. 2E**) or non-specific interaction between DC-SIGN/R and a DHLA-ZW capped control QD (SI, Fig. S6), suggesting minimal binding. Despite some degree of QD quenching being observed for the DC-SIGNR and control samples, the specific QD-DC-SIGN binding was clearly distinguished from these controls through analysis of the FRET ratio (I_{626}/I_{554}) which is linearly correlated to the amounts of QD-bound proteins (SI, Section A55). The apparent FRET ratio for DC-SIGN followed typical binding curves (**Fig. 2F** and SI, Table S1). However, the signals for DC-SIGNR remained low and comparable to non-specific interaction throughout the concentrations tested (SI, Fig. S6G). In fact, the maximum I_{626}/I_{554} value for DC-SIGN binding to QD-PEG$_{13}$-Man/QD-EG$_3$-Man was ~12/~60 times greater than that of the equivalent DC-SIGNR binding, demonstrating a remarkable binding specificity of the QDs for DC-SIGN over DC-SIGNR, two closely-related tetrameric receptors having almost identical protein sequence. To our knowledge, this level of DC-SIGN/R discrimination (ca. 60-fold) is unprecedented for polyvalent ligands built upon such simple carbohydrates. This work thus demonstrates the role of polyvalency in determining multivalent binding selectivity, and opens up a new method for understanding glycobiology where multivalent effects are absolutely essential to biological activity.

The QD-DC-SIGN binding specificity was further verified by a cell based assay. Here, a murine leukemia virus (MLV) vector was used to deliver the luciferase gene to human embryonic kidney cells (293T) previously transfected to express DC-SIGN/R. The MLV vector bearing Ebola virus glycoprotein (EBOV-GP) can bind to cell surface DC-SIGN/R to augment cell entry and gene transduction. [5a,5d] DC-SIGN/R expression in cells markedly increased the gene transduction efficiency. While QD-EG$_3$-Man treatment significantly reduced the gene transduction of DC-SIGN-positive cells in a dose-dependent manner (**Fig. 2G**), presumably via binding to cell surface DC-SIGN, which blocked the binding and entry of the EBOV-GP-bearing vector. In contrast, gene transduction of cells expressing DC-SIGNR was unaffected by QD-EG$_3$-Man. This inhibiting specificity matched perfectly with the QD's much higher affinity to DC-SIGN over DC-SIGNR. Finally, QD-EG$_3$-Man did not modulate significantly the gene transduction of control cells (pcDNA) nor the transduction driven by a control vector bearing vesicular stomatis virus glycoprotein (VSV-G) which cannot use DC-SIGN/R for cell entry (**Fig. 2H**).[5a,5d] These results confirmed that the specific QD-DC-SIGN binding was responsible for the observed inhibition.

Figure 3. (A) A plot of apparent FRET ratio (I_{626}/I_{554}) as a function of DC-SIGN concentration for QD-EG$_3$-Man capped with different percentage of DHLA-EG$_3$-Man ligand: square (100%); cross (50%) and triangle (25%); (B) Normalized DC-SIGN binding efficiency per mannose for QD-EG$_3$-Man at different surface mannose density.

High mannose density appears to favor binding to DC-SIGN over DC-SIGNR. Consistent with this, the high glycan density on HIV (each gp120 contains 25 glycosylation sites)[10] also favors DC-SIGN binding/transfection over WNV whose glycoprotein contains just 1 glycosylation site.[12] Diluting the QD surface DHLA-EG$_3$-Man density with DHLA-ZW strongly affected its DC-SIGN binding. The I_{626}/I_{554} ratios all increased linearly with the increasing protein concentration, except for the 100% QD-EG$_3$-Man at high concentration due to surface binding saturation (**Fig. 3A**). Since the I_{626}/I_{554} ratio is linearly correlated to the amounts of QD-bound proteins (SI, Section A55), the slopes of the binding curves thus represents the binding efficiency (or fraction of added proteins that have bound to the QD). Note, not all added DC-SIGNs may bind to the QD due to natural binding/dissociation equilibrium. The QD-DC-SIGN binding efficiency was decreased rapidly with mannose ligand dilution (**Fig. 3B**), revealing a strong preference of DC-SIGN for binding to multivalent ligands with a high mannose density.

The FRET ratio for DC-SIGN binding to both QDs was found to decrease with increasing temperature (SI, Fig. S7). Assuming that the maximum binding (ca. I_{626}/I_{554}) was independent of temperature, then apparent K_Ds at each temperature were obtained (SI, Table S2). The binding thermodynamic parameters were obtained from an Arrhenius data analysis (**Table 1**). The QD-DC-SIGN binding was found to be enthalpy driven, with QD-EG$_3$-Man giving greater negative enthalpy and entropy changes. Individual CRD-mannose binding was also found to be enthalpy driven from an isothermal titration calorimetry study.[9] Thus the same binding mechanism may be involved in the multivalent QD-DC-SIGN binding.

Table 1. Biophysical and thermodynamic parameters of the DC-SIGN-QD interactions.

QD-probe	Apparent K_D (μM)	K_I (mM)[a]	ΔH (kJ.mol^{-1})	ΔS (J.K^{-1}.mol^{-1})
QD-PEG$_{13}$-Man	0.6±0.1	0.8±0.1	-44 ± 1	-40 ± 2
QD-EG$_3$-Man	0.32±0.07	1.4±0.1	-56 ± 6	-55±18

[a] Inhibition constant of DC-SIGN-QD binding by free mannose.

Figure 4. Schematics of the different DC-SIGN/R-QD-Man multivalent binding. (**A**) Schematic structure of a DC-SIGN/R subunit; (**B**) the uprightly facing DC-SIGN CRDs readily bind to multiple mannoses on the QD, resulting in strong multivalent binding; (C) the sideway pointing CRDs in DC-SIGNR cannot bind to multiple sugars on the QD simultaneously, leading to weak/minimal binding.

The apparent K_Ds for DC-SIGN-QD binding were all in the high nM range (**Table 1**), >5000-fold tighter than individual mannose-CRD binding (K_D = 3.5 mM),[9] indicating multivalent binding greatly enhanced binding affinity. Because the mannose moieties are covalently coupled to a solid, non-deformable and spherical QD core, only receptors having CRDs that face in the same direction are able to bind multivalently to the QD. The minimal DC-SIGNR-QD binding revealed here implies an inability to form effective multivalent binding. Based on their distinct QD-binding properties, we

propose that the CRDs are facing upwardly along the coiled-coil axes in DC-SIGN (hence readily accessible to multivalent binding to the QD), but sideways in DC-SIGNR (hence unavailable to bind the QD multivalently, **Fig. 4**). Such structural models agree well with those proposed from small angle X-ray scattering studies.[13] The different CRD arrangement and accessibility in DC-SIGN/R may account for their distinct viral binding/transmission properties. It also correlates well with the biological roles: the high accessibility of DC-SIGN should enable rapid antigen capture to trigger immune response as required for an antigen presenting dendritic cell surface endocytotic receptor.[11a,14] Whereas the endothelial cell surface adhesion receptor DC-SIGNR [11a] may only recognize specific, spatial and orientation matched multivalent glycans.

In conclusion, an efficient ligand exchange approach for making compact, biocompatible QDs densely capped with specific glycans has been developed, enabling QD-FRET to be employed to probe multivalent receptor-glycan interactions for the 1st time. Compared to other biophysical techniques, QD-FRET has advantages of high sensitivity, rapid, separation-free detection in solution, and ratiometric signal, making detection highly robust and reliable. It can provide quantitative binding thermodynamics and reveal insights of binding site arrangement and accessibility in multimeric proteins. In particular, we reveal that binding sites arrangements in DC-SIGN and DC-SIGNR are functionally distinct and only DC-SIGN binds efficiently to small, spherical multivalent glycan ligands. We further demonstrate that the polyvalent QD specifically inhibits DC-SIGN-, but not DC-SIGNR-, mediated pseudo-Ebola virus entry of target cells in serum media. This work establishes a potential new strategy for targeting DC-SIGN from DC-SIGNR mediated viral infection.

[1] a) I. L. Medintz, A. R. Clapp, H. Mattoussi, E. R. Goldman, B. Fisher, J. M. Mauro, Nat. Mater. 2003, 2, 630-638; b) I. L. Medintz, H. Mattoussi, Phys.Chem.Chem.Phys. 2009, 11, 17-45; c) D. J. Zhou, Biochem. Soc. Trans. 2012, 40, 635-639; d) K. D. Wegner, N. Hildebrandt, Chem. Soc. Rev. 2015, 44, 4792-4834.

[2] a) D. Benito-Alifonso, S. Tremel, B. Hou, H. Lockyear, J. Mantell, D. J. Fermin, P. Verkade, M. Berry, M. C. Galan, Angew. Chem. Int. Ed. 2014, 53, 810-814; b) E. R. Goldman, I. L. Medintz, J. L. Whitley, A. Hayhurst, A. R. Clapp, H. T. Uyeda, J. R. Deschamps, M. E. Lassman, H. Mattoussi, J. Am. Chem. Soc. 2005, 127, 6744-6751; c) W. H. Liu, A. B. Greytak, J. Lee, C. R. Wong, J. Park, L. F. Marshall, W. Jiang, P. N. Curtin, A. Y. Ting, D. G. Nocera, D. Fukumura, R. K. Jain, M. G. Bawendi, J. Am. Chem. Soc. 2010, 132, 472-483; c) X. Qiu, N. Hildebrandt, ACS Nano 2015, 9, 8449-8457; e) Q. Wang, Y. Liu, Y. Ke, H. Yan, Angew. Chem. Int. Ed. 2008, 47, 316-319; f) A. I. Zamaleeva, M. Collot, E. Bahembera, C. Tisseyre, P. Rostaing, A. V. Yakovlev, M. Oheim, M. de Waard, J. M. Mallet, A. Feltz, Nano Lett. 2014, 14, 2994-3001; g) C. Y. Zhang, H. C. Yeh, M. T. Kuroki, T. H. Wang, Nat. Mater. 2005, 4, 826-831; h) H. Y. Zhang, G. Q. Feng, Y. Guo, D. J. Zhou, Nanoscale 2013, 5, 10307-10315; i) X. Zhang, C. A. Marocico, M. Lunz, V. A. Gerard, Y. K. Gun'ko, V. Lesnyak, N. Gaponik, A. S. Susha, A. L. Rogach, A. L. Bradley, ACS Nano 2014, 8, 1273-1283; j) D. J. Zhou, Y. Li, E. A. H. Hall, C. Abell, D. Klenerman, Nanoscale 2011, 3, 201-211; k) K. D. Wegner, Z. Jin, S. Lindén, T. L. Jennings, N. Hildebrandt, ACS Nano 2013, 7, 7411-7419.

[3] a) A. Conway, T. Vazin, D. P. Spelke, N. A. Rode, K. E. Healy, R. S. Kane, D. V. Schaffer, Nat. Nanotech. 2013, 8, 831-838; b) A. Imberty, A. Varrot, Curr. Opin. Struct. Biol. 2008, 18, 567-576; c) S. Kilic, A. L. Bachmann, L. C. Bryan, B. Fierz, Nat. Commun. 2015, 6, 7313; d) M. Mammen, S.-K. Choi, G. M. Whitesides, Angew. Chem. Int. Ed. 1998, 37, 2754-2794.

[4] a) D. Liu, P. T. Snee, ACS Nano 2011, 5, 546-550; b) G. Palui, T. Avellini, N. Q. Zhan, F. Pan, D. Gray, I. Alabugin, H. Mattoussi, J. Am. Chem. Soc. 2012, 134, 16370-16378; c) K. Susumu, H. T. Uyeda, I. L. Medintz, T. Pons, J. B. Delehanty, H. Mattoussi, J. Am. Chem. Soc. 2007, 129, 13987-13996.

[5] a) C. P. Alvarez, F. Lasala, J. Carrillo, O. Muniz, A. L. Corbi, R. Delgado, J. Virol. 2002, 76, 6841-6844; b) H. Feinberg, D. A. Mitchell, K. Drickamer, W. I. Weis, Science 2001, 294, 2163-2166; c) T. B. Geijtenbeek, D. S. Kwon, R. Torensma, S. J. van Vliet, G. C. van Duijnhoven, J. Middel, I. L. Cornelissen, H. S. Nottet, V. N. KewalRamani, D. R. Littman, C. G. Figdor, Y. van Kooyk, Cell 2000, 100, 587-597; d) A. Marzi, P. Moller, S. L. Hanna, T. Harrer, J. Eisemann, A. Steinkasserer, S. Becker, F. Baribaud, S. Pohlmann, J. Infect. Dis. 2007, 196 Suppl 2, S237-246.

[6] a) F. Chiodo, M. Marradi, J. Park, A. F. Ram, S. Penades, I. van Die, B. Tefsen, ACS Chem. Biol. 2014, 9, 383-389; b) R. Ribeiro-Viana, M. Sanchez-Navarro, J. Luczkowiak, J. R. Koeppe, R. Delgado, J. Rojo, B. G. Davis, Nat. Commun. 2012, 3, 1303; c) N. Varga, I. Sutkeviciute, C. Guzzi, J. McGeagh, I. Petit-Haertlein, S. Gugliotta, J. Weiser, J. Angulo, F. Fieschi, A. Bernardi, Chem. Eur. J. 2013, 19, 4786-4797.

[7] N. P. Chung, S. K. Breun, A. Bashirova, J. G. Baumann, T. D. Martin, J. M. Karamchandani, J. W. Rausch, S. F. Le Grice, L. Wu, M. Carrington, V. N. Kewalramani, J. Biol. Chem. 2010, 285, 2100-2112.

[8] C. W. Davis, H. Y. Nguyen, S. L. Hanna, M. D. Sanchez, R. W. Doms, T. C. Pierson, J. Virol. 2006, 80, 1290-1301.

[9] A. Holla, A. Skerra, Prot. Engin. Des. Select. 2011, 24, 659-669.

[10] L. Kong, I. A. Wilson, P. D. Kwong, Proteins 2015, 83, 590-596.

[11] Y. Guo, H. Feinberg, E. Conroy, D. A. Mitchell, R. Alvarez, O. Blixt, M. E. Taylor, W. I. Weis, K. Drickamer, Nat. Struct. Mol. Biol. 2004, 11, 591-598.

[12] R. Kanai, K. Kar, K. Anthony, L. H. Gould, M. Ledizet, E. Fikrig, W. A. Marasco, R. A. Koski, Y. Modis, J. Virol. 2006, 80, 11000-11008.

[13] G. Tabarani, M. Thepaut, D. Stroebel, C. Ebel, C. Vives, P. Vachette, D. Durand, F. Fieschi, J. Biol. Chem. 2009, 284, 21229-21240.

[14] A. Cambi, I. Beeren, B. Joosten, J. A. Fransen, C. G. Figdor, Eur. J. Immun. 2009, 39, 1923-1928.

Quantum Dot-FRET

Yuan Guo,* Chadamas Sakonsinsiri,
Inga Nehlmeier, Martin A. Fascione,
Haiyan Zhang, Weili Wang, Stefan
Pöhlmann, W. Bruce Turnbull, and
Dejian Zhou*

_____ **Page – Page**

Compact, Polyvalent Mannose-
Quantum Dots as Sensitive, Ratiometric
FRET Probes for Multivalent Protein-
Ligand Interactions

Compact, dense polyvalent mannose capped quantum dots have been prepared
by a new, highly-efficient ligand exchange approach and successfully employed as
novel structural and mechanistic probes for multivalent protein-glycan interactions
underpinning the HIV/Ebola viral infections via a rapid, sensitive and ratiometric
readout strategy based on the Förster resonance energy transfer for the first time.